# ADCT catalysts: ADC Therapeutics SA PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/adct/catalysts

> ADC Therapeutics SA (ADCT) has no upcoming catalysts in this calendar. The latest recorded is the ADC Therapeutics SA earnings report, November 9, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ADC Therapeutics SA |
| Ticker | ADCT (NYSE) |
| SEC CIK | 1771910 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/adct |

## Cash runway

Cash $189.2M as of 2026-09-30; quarterly burn $27.9M; about 20.4 months of runway at that rate (XBRL company facts, accession 0001628280-26-072178).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 23, 2021 | [Zynlonta (loncastuximab tesirine-lpyl) FDA approval](https://sec-api.dev/pdufa/loncastuximab-tesirine-lpyl) | ADCT |  | completed, approved | "BLA761196 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210423, review_priority PRIORITY; sponsor_name ADC Therapeutics SA; product ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761196%22)) |
| March 27, 2025 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828025015057/adct-20241231pressrelease.htm)) |
| Q2 2025 | [ZYNLONTA (zynlonta) interim data readout](https://sec-api.dev/pdufa/zynlonta) | ADCT |  | scheduled | "Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828025015057/adct-20241231pressrelease.htm)) |
| May 14, 2025 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828025025329/adct-20250331pressrelease.htm)) |
| August 12, 2025 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000177191025000006/adct-20250630pressrelease.htm)) |
| November 10, 2025 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828025050796/adct-20250930pressrelease.htm)) |
| March 10, 2026 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016238/adctq425pressrelease.htm)) |
| March 31, 2026 | [Loncastuximab tesirine primary completion](https://sec-api.dev/pdufa/loncastuximab-tesirine) | ADCT | Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma | completed | "NCT04384484 (Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-31 (ACTUAL); Lead Sponsor ADC Therapeutics S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04384484)) |
| Q2 2026 | [Loncastuximab topline data readout](https://sec-api.dev/pdufa/loncastuximab) | ADCT |  | scheduled | "The Company continues to expect to announce topline results from the LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in the second quarter of 2026, with full results anticipated by year-end." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/adct-20260331pressrelease.htm)) |
| May 4, 2026 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/adct-20260331pressrelease.htm)) |
| August 13, 2026 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/dp251718_ex9901.htm)) |
| late 2026 | [ADC Therapeutics SA topline data readout](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | scheduled | ""We expect topline LOTIS-5 results in the second quarter, followed by full LOTIS-5 and LOTIS-7 results in 2L+ DLBCL by the end of 2026 and, assuming positive data, potential compendia inclusions in first half of 2027 with LOTIS-5 regulatory approval to follow." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016238/adctq425pressrelease.htm)) |
| Q4 2026 | [TRUXIMA® (rituximab) NDA/BLA submission](https://sec-api.dev/pdufa/rituximab) | ADCT |  | scheduled | "ADC Therapeutics expects to submit an sBLA in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/dp248849_ex9901.htm)) |
| November 9, 2026 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828026071899/adct-20260930pressrelease.htm)) |

## Drugs

- [Loncastuximab](https://sec-api.dev/pdufa/loncastuximab): 
- [Loncastuximab tesirine](https://sec-api.dev/pdufa/loncastuximab-tesirine): Relapsed Diffuse Large B-Cell Lymphoma
- [Zynlonta (loncastuximab tesirine-lpyl)](https://sec-api.dev/pdufa/loncastuximab-tesirine-lpyl): 
- [ZYNLONTA (zynlonta)](https://sec-api.dev/pdufa/zynlonta): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/adct/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ADCT catalysts: ADC Therapeutics SA PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/adct/catalysts

```bibtex
@misc{secapidev_companies_adct_catalysts_20261116,
  title        = {ADCT catalysts: ADC Therapeutics SA PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/adct/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_adct_catalysts_20261116","title":"ADCT catalysts: ADC Therapeutics SA PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/adct/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
